Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus azacitidine + vorinostat in relapsed acute myeloid leukemia
2011-005207-32Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- May 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) comparing Azacitidine with Azacitidine + vorinostat (2 arms). Primary endpoints: Overall response rate and Overall survival. Status: unknown.
02
Drugs
azacitidinevorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-005207-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005207-32.